GERD-related inflammation may contribute to esophageal cancer risk

Inflammation might be an important factor in the progression from reflux to esophageal cancer, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

"Our research shows that damage to the esophageal lining that can be seen with endoscopy is important in the progression from normal cells to cancer, and Barrett's esophagus is likely to be an intermediate step," said Rune Erichsen, MD, of Aarhus University Hospital and lead author of this study.

In the past three decades, the incidence of has increased dramatically in the U.S. and Europe. It is estimated that as many as 10,000 new cases will be diagnosed each year in the U.S. In addition, the risk of death associated with the is substantial.

Gastroesophageal reflux disease (GERD) is a key risk factor for esophageal cancer. The specific role of inflammation of the lining of the esophagus from GERD — clinically known as erosive reflux disease — is less clear.

"Although reflux with a history of inflammation, irritation or swelling of the esophagus are at increased risk for esophageal cancer, the absolute risk of cancer even in these patients is very low," added Dr. Erichsen.

Using data from population-based Danish medical registries (1996 through 2008) of 33,849 patients with reflux disease, a team of researchers performed a nationwide cohort study. They found that 26,194 of the patients (77 percent) had erosive reflux disease and 37 subsequently developed esophageal cancer after a mean follow-up time of 7.4 years. The incidence of cancer among patients with erosive reflux disease was significantly greater than that expected for the general population. However, of the 7,655 patients with nonerosive reflux disease, only one was diagnosed with esophageal cancer after 4.5 years of follow-up.

More information: To learn more about GERD, please read the AGA brochure, "Understanding Heartburn and Reflux Disease" at www.gastro.org/patient-center/… tions/heartburn-gerd

add to favorites email to friend print save as pdf

Related Stories

Erosive, but not nonerosive, GERD ups esophageal CA risk

Apr 26, 2012

(HealthDay) -- Patients with gastroesophageal reflux disease with a history of esophagitis are at increased risk for esophageal adenocarcinoma, although the absolute risk is low, according to a study published in the May ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

39 minutes ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

4 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

Immunotherapy set to revolutionise cancer treatment

5 hours ago

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

PeterD
not rated yet May 11, 2012
This has been known for at least 20 years.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.